Brainstorm Cell Therapeutics(DE:GHD)
€2.690.00 (0.00%)
DE:GHD
Brainstorm Cell Therapeutics financials statements
€2.69
At close:0.00 (0.00%)
Brainstorm Cell Therapeutics (GHD) Ratios
1 Followers
Brainstorm Cell Therapeutics Ratios
DE:GHD's free cash flow for Q2 2026 was $-895.00K. For the 2026 fiscal year, DE:GHD's free cash flow was increased by $0.00 and operating cash flow was $-895.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.03 | 0.04 | 0.24 | 0.35 | 3.69 |
| Quick Ratio | 0.03 | 0.04 | 0.24 | 0.35 | 3.69 |
| Cash Ratio | 0.00 | 0.02 | 0.17 | 0.09 | 2.98 |
| Solvency Ratio | -0.92 | 1.24 | -1.87 | -2.09 | -2.44 |
| Operating Cash Flow Ratio | -0.63 | -1.01 | -2.62 | -2.20 | -4.16 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -33.93 | 0.00 | 0.00 |
| Net Current Asset Value | $ -10.70M | $ -9.21M | $ -7.17M | $ -8.36M | $ 13.35M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.29 | 0.39 | 0.30 | 0.48 | 0.17 |
| Debt-to-Equity Ratio | -0.02 | -0.09 | -0.26 | -1.36 | 0.26 |
| Debt-to-Capital Ratio | -0.02 | -0.10 | -0.36 | 3.80 | 0.21 |
| Long-Term Debt-to-Capital Ratio | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.07 | -0.24 | -0.87 | -2.80 | 1.51 |
| Debt Service Coverage Ratio | 0.00 | -146.83 | -28.07 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | -151.86 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.04 | 0.00 | 0.04 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.15 | 0.33 | 1.67 | 2.09 |
| Net Debt to EBITDA | -0.02 | -0.05 | 0.00 | -0.14 | 0.57 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 103.56% | -99.40% | 80.19% | 97.80% | 99.67% |
| Return on Assets (ROA) | -1441.54% | 634.44% | -408.56% | -287.27% | -83.54% |
| Return on Equity (ROE) | 100.15% | -149.70% | 353.89% | 805.21% | -126.45% |
| Return on Capital Employed (ROCE) | 96.71% | 163.63% | 596.85% | 7112.32% | -106.88% |
| Return on Invested Capital (ROIC) | 98.70% | 177.25% | 717.26% | -2302.60% | -100.48% |
| Return on Tangible Assets | -1441.54% | 634.44% | -408.85% | -287.27% | -83.59% |
| Earnings Yield | -202.18% | 96.43% | -109.22% | -40.36% | -16.81% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.04 | 0.05 | 0.05 | 0.07 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -9246.67 | -6823.43 | -7971.09 | -5194.23 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 9246.67 | 6823.43 | 7971.09 | 5194.23 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.75 | -1.71 | -5.33 | -7.90 | -10.83 |
| Free Cash Flow Per Share | -0.75 | -1.71 | -5.33 | -7.91 | -10.97 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -1136.56 | -666.21 | -79.59 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -1136.56 | -666.21 | -79.59 |
| Operating Cash Flow Coverage Ratio | -33.53 | -12.63 | -16.05 | -4.72 | -5.17 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -136.82% | -75.44% | -130.09% | -32.17% | -18.28% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.50 | 1.04 | -0.92 | -2.48 | -5.95 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.50 | -1.55 | -3.24 | -19.95 | 7.52 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.73 | -1.33 | -0.77 | -3.11 | -5.47 |
| Price-to-Operating Cash Flow Ratio | -0.73 | -1.33 | -0.77 | -3.11 | -5.54 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.01 | 0.02 | 1.56 | 0.21 |
| Enterprise Value Multiple | -0.54 | -1.11 | -0.93 | -2.65 | -5.42 |
| Enterprise Value | 5.28M | 12.59M | 15.72M | 63.47M | 131.70M |
| EV to EBITDA | -0.54 | -1.11 | -0.93 | -2.65 | -5.42 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.76 | -1.38 | -0.77 | -3.28 | -4.95 |
| EV to Operating Cash Flow | -0.76 | -1.38 | -0.77 | -3.29 | -5.01 |
| Tangible Book Value Per Share | -1.11 | -1.46 | -1.27 | -1.23 | 7.97 |
| Shareholders’ Equity Per Share | -1.11 | -1.46 | -1.27 | -1.23 | 7.98 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.11 | 2.19 | -4.48 | -9.93 | -10.09 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.04 | -1.01 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.68 | 0.78 | 1.19 | 0.80 | 1.07 |
Currency in USD
